Search clinical trials for: PD-1 Receptor

Total 62394 results

Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms

Brazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Recurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant Tumors

China
CureVac
Syneos Health; Cromos Pharma LLC

Active, not recruiting

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Carcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and Neck

Spain, France, Austria, Germany, Russian Federation
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Georgiamune Inc

Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Solid Tumor | Melanoma Stage IV

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Merck Sharp & Dohme LLC

Terminated

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Advanced Solid Tumors

France, Germany, Spain, United Kingdom
Shandong New Time Pharmaceutical Co., LTD

Recruiting

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Solid Tumors

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Tislelizumab in Addition to BACE in Patients With NSCLC

NSCLC

China
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...

Active, not recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Breast Cancer | Neoadjuvant Chemotherapy

China
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

Healthy Male Adults

Japan
New York State Psychiatric Institute
Bristol-Myers Squibb; National Institute of Mental Health (NIMH); Otsuka Pharmaceutical...

Terminated

Treatment of Children With ADHD Who do Not Fully Respond to Stimulants (TREAT)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia (ASPIRE)

Schizophrenia

United States, India, South Africa, Estonia, Russian Federation, Mexico, Korea, Republic of, Malaysia, Bulgaria, Hungary, Croatia, Serbia, Poland, Romania, Puerto Rico, Slovakia, Chile, Taiwan, Thailand, Australia, Spain, Argentina, Finlan... and more
University Health Network, Toronto
University of British Columbia; McGill University; Centre for Addiction and Mental... and other collaborators

Completed

Canadian Biomarker Integration Network for Depression Study (CAN-BIND-1)

Major Depressive Disorder

Canada
Janssen Research & Development, LLC

Completed

Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

Immunoassay | Antipsychotic

Belgium
Fundación Marques de Valdecilla
Centro de Investigación Biomédica en Red de Salud Mental; Instituto de Investigación...

Completed

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up (PAFIP2_nc1Y)

Psychotic Disorders | Schizophrenia

Spain
University of Sao Paulo

Unknown

Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients (ARIQUELI)

Bipolar I Disorder

Brazil
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole in Adolescents With Schizophrenia (APEX 239)

Schizophrenia

United States, Puerto Rico
Peking University
Ministry of Science and Technology of the People´s Republic of China

Unknown

Standard Comprehensive Intervention to Treat First-episode Schizophrenia

Schizophrenia

China
Eli Lilly and Company

Completed

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Schizophrenia

United States
University of Medicine and Dentistry of New Jersey
Bristol-Myers Squibb

Completed

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

Schizophrenia | Schizoaffective Disorder | Social Anxiety Disorder

United States
Cairo University

Not yet recruiting

Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study

Lichen Planus

Egypt
Merck Sharp & Dohme LLC

Active, not recruiting

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Neoplasms

Poland, United States, Australia, Canada, China, France, Greece, Israel, Japan, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

Melanoma
Merck Sharp & Dohme LLC

Completed

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

Neoplasms
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine
Merck Sharp & Dohme LLC

Completed

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Primary Mediastinal B-Cell Lymphoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

Cancer | Solid Tumor
Merck Sharp & Dohme LLC

Terminated

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Multiple Myeloma
University of Chicago

Withdrawn

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

Head and Neck Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

Carcinoma, Hepatocellular

Korea, Republic of, China, Hong Kong, Malaysia, Taiwan
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Sichuan Cancer Hospital and Research Institute

Recruiting

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Apatinib | PD-1 Antibody | Transarterial Chemoembolization

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

HIV Infections | HIV-1-infection | PD-L1 Gene Mutation

China
Sun Yat-sen University

Recruiting

G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

PD-1 Inhibitor | Granulocyte Colony-Stimulating Factor

China
PDC*line Pharma SAS

Active, not recruiting

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Non Small Cell Lung Cancer

Belgium, France, Netherlands, Germany, Poland
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Jiangsu vcare pharmaceutical technology co., LTD

Completed

Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19

Healthy Subjects | PK/PD

China
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Adenocarcinoma | Gastroesophageal Junction
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

Australia, United States, Canada, Chile, Taiwan, Argentina
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Melanoma

Canada, United States, Australia, Belgium, Brazil, Chile, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, Switzerland, United Kingdom

Search clinical trials for: PD-1 Receptor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations